Cargando…
Compelling Benefit of Soluble Suppression of Tumorigenicity‐2 in Post–Myocardial Infarction Estimation of Risk: The Time Is Right for Its Routine Use in the Clinic
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721902/ https://www.ncbi.nlm.nih.gov/pubmed/29054841 http://dx.doi.org/10.1161/JAHA.117.007665 |
| _version_ | 1783284909383614464 |
|---|---|
| author | Díez, Javier Bayes‐Genis, Antoni |
| author_facet | Díez, Javier Bayes‐Genis, Antoni |
| author_sort | Díez, Javier |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-5721902 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2017 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-57219022017-12-12 Compelling Benefit of Soluble Suppression of Tumorigenicity‐2 in Post–Myocardial Infarction Estimation of Risk: The Time Is Right for Its Routine Use in the Clinic Díez, Javier Bayes‐Genis, Antoni J Am Heart Assoc Editorial John Wiley and Sons Inc. 2017-10-20 /pmc/articles/PMC5721902/ /pubmed/29054841 http://dx.doi.org/10.1161/JAHA.117.007665 Text en © 2017 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
| spellingShingle | Editorial Díez, Javier Bayes‐Genis, Antoni Compelling Benefit of Soluble Suppression of Tumorigenicity‐2 in Post–Myocardial Infarction Estimation of Risk: The Time Is Right for Its Routine Use in the Clinic |
| title | Compelling Benefit of Soluble Suppression of Tumorigenicity‐2 in Post–Myocardial Infarction Estimation of Risk: The Time Is Right for Its Routine Use in the Clinic |
| title_full | Compelling Benefit of Soluble Suppression of Tumorigenicity‐2 in Post–Myocardial Infarction Estimation of Risk: The Time Is Right for Its Routine Use in the Clinic |
| title_fullStr | Compelling Benefit of Soluble Suppression of Tumorigenicity‐2 in Post–Myocardial Infarction Estimation of Risk: The Time Is Right for Its Routine Use in the Clinic |
| title_full_unstemmed | Compelling Benefit of Soluble Suppression of Tumorigenicity‐2 in Post–Myocardial Infarction Estimation of Risk: The Time Is Right for Its Routine Use in the Clinic |
| title_short | Compelling Benefit of Soluble Suppression of Tumorigenicity‐2 in Post–Myocardial Infarction Estimation of Risk: The Time Is Right for Its Routine Use in the Clinic |
| title_sort | compelling benefit of soluble suppression of tumorigenicity‐2 in post–myocardial infarction estimation of risk: the time is right for its routine use in the clinic |
| topic | Editorial |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721902/ https://www.ncbi.nlm.nih.gov/pubmed/29054841 http://dx.doi.org/10.1161/JAHA.117.007665 |
| work_keys_str_mv | AT diezjavier compellingbenefitofsolublesuppressionoftumorigenicity2inpostmyocardialinfarctionestimationofriskthetimeisrightforitsroutineuseintheclinic AT bayesgenisantoni compellingbenefitofsolublesuppressionoftumorigenicity2inpostmyocardialinfarctionestimationofriskthetimeisrightforitsroutineuseintheclinic |